News

Conventional LFTs Often Miss Liver Disease in Type 2 Diabetes

Publish date: October 5, 2011

 

FROM THE ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

The ET2DS study is funded by Pfizer. Dr. Williamson reported having no financial conflicts of interest.

Pages

Recommended Reading

Nearly Half of Giardiasis Patients Report Fatigue or IBS at 3 Years
MDedge Internal Medicine
Lymph Node Target Questioned in Colon Cancer Surgery
MDedge Internal Medicine
Metronidazole Equals Vancomycin in C. Diff. Diarrhea
MDedge Internal Medicine
Mortality Low With Conservative Management of Necrotizing Pancreatitis
MDedge Internal Medicine
Deferasirox Can Improve Liver Fibrosis, Necroinflammation
MDedge Internal Medicine
Mallory-Denk Bodies on Biopsy Predict Fibrosis Progression in HCV
MDedge Internal Medicine
Diseases of the Gut May Present Cutaneously
MDedge Internal Medicine
Rule Helped Detect Asymptomatic C. difficile Carriers
MDedge Internal Medicine
Obesity May Explain Liver Cancer Hike Among Latinos
MDedge Internal Medicine
Reflux Surgery Redos Safe; Outcomes Not Always Optimal
MDedge Internal Medicine